AUS
NZ
UK
CA
USA
IND
_12_11_2024_11_07_35_314829.jpg)
Highlights:
- Graft Polymer announces positive pre-clinical results for AW21003 in collaboration with Awakn Life Sciences.
- AW21003 demonstrates safety and efficacy in enhancing learning and social behaviours without adverse side effects.
- Research programme to expand compound screening and focus on brain chemistry impacts like serotonin and dopamine.
Graft Polymer (UK) PLC (LSE:GPL) has revealed encouraging initial findings from a pre-clinical study of AW21003, a novel compound developed in partnership with Awakn Life Sciences. Designed to treat trauma-related mental health conditions, including Post-Traumatic Stress Disorder (PTSD), the study marks significant progress in the development of safer and more effective therapeutic options.
Positive Early Results
Conducted by the University of Nottingham, the study is part of a collaboration focusing on aminoindanes, compounds with potential to enhance pro-social behaviours like trust and empathy. These behaviours are critical for addressing PTSD symptoms. AW21003, unlike other treatments such as MDMA, showed no repetitive or compulsive behaviours, suggesting a safer therapeutic profile.
One of the key findings of the study was the compound’s positive impact on learning and memory. Animals treated with AW21003 were able to learn and retain information effectively, as demonstrated by their ability to select a correct diet after a demonstration. Researchers noted this enhanced learning capacity as a sign of potential improvements in social interactions, vital for PTSD recovery.
Additionally, unique behavioural patterns were observed in the treated animals, pointing to possible benefits beyond traditional PTSD symptoms. These observations pave the way for further investigation into the compound’s broader therapeutic effects.
Expanding Research Efforts
Building on these promising results, the programme plans to synthesise and evaluate additional aminoindane compounds. These will undergo rigorous testing to determine their impact on key brain chemicals, including serotonin and dopamine. The continuation of testing at the University of Nottingham will focus on validating the compound’s effects and identifying the most effective formulations.
Expert Endorsement
Professor David Nutt, Senior Scientific Advisor to Graft Polymer, highlighted the significance of these findings:
"These findings represent an important milestone for our aminoindane programme. Developing compounds that combine therapeutic efficacy with improved safety has transformative potential for treating PTSD and other trauma-related conditions."
Addressing a Global Challenge
PTSD impacts an estimated 20 million individuals across the US, UK, and Europe, underscoring the urgent need for innovative treatments. Graft Polymer’s progress in developing AW21003 offers a hopeful path forward for addressing this widespread mental health challenge. The collaboration with Awakn Life Sciences aims to continue advancing research to deliver effective and safe solutions for those suffering from trauma-related conditions.
The next phase of research will focus on fine-tuning the compound’s profile and ensuring its suitability for clinical trials, bringing the goal of a transformative treatment closer to reality.
